Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 6/20 | 0.39 |
| ▸ | RARB | P10826 | 6/20 | 0.39 |
| ▸ | RARG | P13631 | 6/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098893 | 0.91 | RARA (0.34) | RARARARBRARG | |
| SCHEMBL2098921 | 0.84 | CYP1A2 (0.31) | CYP1A2TSHR | |
| SCHEMBL2098474 | 0.78 | HCAR3 (0.34) | HCAR3CNR2 | |
| SCHEMBL2098396 | 0.76 | RARB (0.50) | RARARARBRARGHCAR3 | |
| SCHEMBL2098114 | 0.72 | RARA (0.39) | RARARARBRARGHCAR3CYP2C9 | |
| SCHEMBL7714825 | 0.72 | THRA (0.40) | — | |
| SCHEMBL7717696 | 0.72 | RARA (0.42) | RARARARBRARGCYP1A2CYP3A4 | |
| SCHEMBL9130944 | 0.72 | ALDH1A1 (0.49) | CNR2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL7715241 | 0.70 | THRA (0.49) | — | |
| SCHEMBL2098706 | 0.70 | CA12 (0.36) | RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163952-B2 | RAR receptor agonist ligands and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2146951-B1 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100261754-A1 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261754-A1 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.